| General Information of Drug Metabolite (DM) (ID: DM002768) |
| DM Name |
9-Aminocamptothecin metabolite M2
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 1A1 (CYP1A1)
|
DME0006
|
| Unclear - Unclear |
NSC-603071
|
[1] |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Unclear - Unclear |
NSC-603071
|
[1] |
|
|
|
|
|
|
|
| DME(s) Metabolizing This DM |
| DME Name |
DME ID |
Product |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 1A1 (CYP1A1)
|
DME0006
|
| Unclear - Unclear |
NSC-603071
|
[1] |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Unclear - Unclear |
NSC-603071
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| NSC-603071 |
DR1862
|
Phase 2 |
Ovarian cancer |
|
|
| References |
| 1 |
Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy. Int J Oncol. 2014 Aug;45(2):877-86.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
